serum ca19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients血清ca19-9水平与代谢控制和糖尿病患者的胰腺β细胞的功能.pdfVIP

Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 745189, 5 pages doi:10.1155/2012/745189 Clinical Study Serum CA19-9 Level Associated with Metabolic Control and Pancreatic Beta Cell Function in Diabetic Patients Haoyong Yu,1, 2 Ruixia Li,2, 3 Lei Zhang,2 Haibing Chen,2 Yuqian Bao,2 and Weiping Jia2 1 School of Medicine, Shanghai Jiao Tong University, Shanghai 200233, China 2 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affi liated Sixth People’s Hospital, Shanghai Diabetes Institute, Shanghai Clinical Center of Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China 3 Department of medicine, Soochow University, Soochow 215006, China Correspondence should be addressed to Weiping Jia, wpjia@sjtu.edu.cn Received 10 January 2012; Revised 15 March 2012; Accepted 15 April 2012 Academic Editor: Chien-Jen Chen Copyright © 2012 Haoyong Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CA19-9 is a tumor-associated antigen. It is also a marker of pancreatic tissue damage that might be caused by diabetes. Long-term poor glycemic control may lead to pancreatic beta cell dysfunction which is reflected by elevated serum CA19-9 level. Intracellular cholesterol accumulation leads to islet dysfunction and impaired insulin secretion which provide a new lipotoxic model. This study firstly found total cholesterol was one of the independent contributors to CA19-9. Elevated serum CA19-9 level in diabetic patients may indicate further investigations of glycemic control, pancreatic beta cell function, and total cholesterol level. 1. I